GSK strong finish expected, says Barclays

GSK PLC (LSE:GSK, NYSE:GSK) should deliver better than expected fourth-quarter results on January 31, according to Barclays, amid heightened expectations driven by the robust performance of its RSV vaccine, Arexvy. Analysts at the bank, who also wondered if 2024 could be "the year Zantac goes away?", said the last set of quarterly results were muddied by the performance of Arexvy. "Though Arexvy's result at 3Q created a lot of confusion, with the inventory stocking benefit and launch costs [were] somewhat u ...